Is ZIM Laboratories Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, ZIM Laboratories Ltd (ZIMLAB.NS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is ZIM Laboratories Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes ZIM Laboratories Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of ZIM Laboratories Ltd?

Muslim investors may consider investing in ZIM Laboratories Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is ZIM Laboratories Ltd classified as HALAL?

Musaffa determines the Shariah status of ZIM Laboratories Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for ZIM Laboratories Ltd updated?

The Shariah compliance status of ZIM Laboratories Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like ZIM Laboratories Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of ZIM Laboratories Ltd?

You can check the latest Shariah compliance status of ZIM Laboratories Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

ZIMLAB.NS Shariah Compliance

Screening Methodology: AAOIFI

HALAL

Last Updated: March 12, 2026

Report Source: 2026 3rd Quarter Report

ZIM Laboratories Ltd. Stock Analysis ZIMLAB.NS

India Health Care Nano Cap Report: Q3, 2026

Zim Laboratories Ltd. is a pharmaceutical company. The company is headquartered in Nagpur, Maharashtra and currently employs 577 full-time employees. The company went IPO on 2018-06-08. The firm develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. The company is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.

Key Statistics of ZIM Laboratories Ltd (ZIMLAB.NS)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

₹95.02₹103.00

Today's Open

₹102.99

Volume

41.58K

P/E Ratio (TTM)

46.22

52 Week Range

₹59.31₹127.00

Market Cap

3.90B

Avg. Volume

147.89K

Dividend Yield

0.01%

Financial Metrics & Statements of ZIM Laboratories Ltd (ZIMLAB.NS)

FAQ's for ZIM Laboratories Ltd (ZIMLAB.NS)

According to Musaffa’s Shariah screening methodology, ZIM Laboratories Ltd (ZIMLAB.NS) is currently classified as HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.